Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability
- PMID: 19919895
- DOI: 10.1016/j.bmcl.2009.10.062
Novel sulfamoyl benzamides as selective CB(2) agonists with improved in vitro metabolic stability
Abstract
A lead optimization campaign in our previously reported sulfamoyl benzamide class of CB(2) agonists was conducted to improve the in vitro metabolic stability profile in this series while retaining high potency and selectivity for the CB(2) receptor. From this study, compound 14, N-(3,4-dimethyl-5-(morpholinosulfonyl)phenyl)-2,2-dimethylbutanamide, was identified as a potent and selective CB(2) agonist exhibiting moderate in vitro metabolic stability and oral bioavailability. Compound 14 demonstrated in vivo efficacy in a rat model of post-surgical pain.
Copyright 2009 Elsevier Ltd. All rights reserved.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Chemical Information